Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Buy" from Brokerages

Key Points

• Oruka Therapeutics, Inc. (NASDAQ:ORKA) has received a **consensus "Buy" rating** from five brokerage firms, with an average target price of **$42.00**.
• Hedge funds and institutional investors have recently increased their stakes in Oruka Therapeutics, indicating growing interest, with 56.44% of the company's stock now held by such investors.
• The company recently reported a quarterly earnings per share of **($0.46)**, slightly beating analysts' estimates of ($0.48) per share.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has received an average recommendation of "Buy" from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $42.00.

ORKA has been the subject of several research analyst reports. BTIG Research increased their target price on shares of Oruka Therapeutics from $44.00 to $56.00 and gave the stock a "buy" rating in a research note on Wednesday, September 17th. Wall Street Zen raised shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, September 20th. Wedbush reaffirmed an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 12th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Monday, August 18th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Legal & General Group Plc purchased a new position in shares of Oruka Therapeutics in the second quarter valued at approximately $28,000. Ameritas Investment Partners Inc. purchased a new position in shares of Oruka Therapeutics in the second quarter valued at approximately $31,000. BNP Paribas Financial Markets boosted its stake in shares of Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock valued at $31,000 after purchasing an additional 2,306 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Oruka Therapeutics in the second quarter valued at approximately $68,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Oruka Therapeutics in the second quarter valued at approximately $96,000. Hedge funds and other institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Trading Up 1.0%

Shares of ORKA opened at $15.20 on Friday. Oruka Therapeutics has a 12-month low of $5.49 and a 12-month high of $31.13. The firm has a 50-day moving average price of $14.90 and a 200 day moving average price of $12.37. The firm has a market capitalization of $569.26 million, a P/E ratio of -5.41 and a beta of -0.26.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.02. Equities research analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.